Loading…
Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.
Chinese biotech providing antibody-discovery platforms and genetically humanized mouse models for drug research.
Earns fees for supplying gene-edited mice and running research studies on them, plus up-front and milestone payments when drug makers license antibodies found with its RenMice platform. The same company is also listed in Hong Kong as 2315.
In one line: A China-based antibody-discovery/CRO platform, like a smaller Genentech-tools peer.
Moat: narrow (IP / patents, installed base). Proprietary mouse-model platform used broadly by global biopharma partners.
Headquarters: Beijing, China · Employees: 1,443
Size Biocytogen Pharmaceuticals (Beijing) (688796.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $2.22B, the 1152nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥78.46 on 6 Nov 2026.
Performance Over six months the shares fell 18.6%, against +3.1% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 40.5% over the last twelve months (peer median +12.2%); the operating margin is 23.6% (peer median 12.2%).
Valuation It trades at 92.6× forward earnings against a peer median of 20.2× (2nd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +41%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.8 points above its cost of capital (11.1% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.65B | CN¥1.34B | CN¥999M | CN¥720M | CN¥548M |
| Revenue growth | — | +35% | +39% | +31% | — |
| Gross profit | CN¥1.29B | CN¥940M | CN¥684M | CN¥423M | CN¥308M |
| EBITDA | CN¥541M | CN¥358M | CN¥301M | -CN¥128M | -CN¥459M |
| Net income | CN¥357M | CN¥169M | CN¥34.2M | -CN¥385M | -CN¥618M |
| Free cash flow | CN¥134M | CN¥260M | CN¥159M | -CN¥211M | -CN¥563M |
| Capital expenditure | CN¥272M | CN¥85.6M | CN¥37.8M | CN¥127M | CN¥247M |
| Total debt | n/a | CN¥919M | CN¥1.27B | CN¥1.32B | CN¥1.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | $2.22B | -19% | +40% | 24% | 92.6× | 32.3% |
| OmniAb OABI | $734M | +29% | +91% | -116% | n/a | 59.6% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| AbCellera Biologics ABCL | $3.85B | +149% | +101% | -340% | n/a | n/a |
| Genscript Biotech 1548.HK | $8.81B | +96% | +53% | 12% | 297.9× | 36.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688796.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -36.2% | +0.5% | 2nd lowest of 21 |
| 6-month return | -18.6% | +3.1% | 5th lowest of 21 |
| Distance from 52-week high | -49.4% | -26.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +40.5% | +12.2% | 2nd highest of 19 |
| Operating margin | 23.6% | 12.2% | 5th highest of 20 |
| Forward P/E | 92.6× | 20.2× | 2nd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 32.3% | 5.2% | 5th most demanding of 16 |
| Growth delivered (Del g) | +41.1% | +11.6% | highest of 15 |
| Hurdle (Req g minus delivered) | -8.8 pp | -7.9 pp | 8th least demanding of 15 |
| ROIC minus cost of capital | +1.8 pp | +0.5 pp | 8th highest of 18 |
| EV / EBITDA | 27.0× | 10.9× | most expensive of 9 |
| Net debt / EBITDA | -0.3× | 0.2× | 3rd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Biocytogen Pharmaceuticals (Beijing) 688796.SS | China | $2.22B | -19% | +40% | 24% | 92.6× | 32.3% | +41.1% |
| China Automotive Engineering Research Institute 601965.SS | China | $2.18B | -8% | +12% | 24% | 13.2× | -5.6% | +7.9% |
| TIC Solutions TIC | United States | $2.26B | +5% | +39% | -1% | n/a | 51.8% | n/a |
| Firstsource Solutions FSL.NS | India | $2.16B | +25% | +20% | 12% | 22.0× | 20.3% | +13.5% |
| Sagility SAGILITY.NS | India | $2.15B | +2% | +28% | 18% | 16.4× | 10.3% | +19.5% |
| Suzhou Nanomicro Technology 688690.SS | China | $2.31B | +17% | +26% | 25% | 57.1× | 35.3% | +35.2% |
| Sigurd Microelectronics 6257.TW | Taiwan | $2.33B | -19% | +12% | 22% | 14.0× | n/a | n/a |
| Ardentec 3264.TWO | Taiwan | $2.36B | -30% | +32% | 30% | 12.3× | 5.2% | +7.7% |
| V2X VVX | United States | $2.39B | +9% | +13% | 4% | 11.3× | -1.4% | +26.3% |
| Shanghai GenTech 688596.SS | China | $2.42B | +56% | +4% | 2% | 76.5× | n/a | n/a |
| S-1 012750.KS | South Korea | $2.45B | +14% | +1% | 7% | 21.8× | -1.2% | +5.4% |
| KWS SAAT SE & Co KGaA KWS.DE | Germany | $2.48B | -12% | -3% | 15% | 13.2× | -8.2% | +4.4% |
| Visional 4194.T | Japan | $2.51B | +32% | +24% | 25% | 20.2× | -2.4% | +28.2% |
| CECEP Environmental Protection 300140.SZ | China | $2.51B | -18% | -2% | 23% | n/a | -1.2% | +26.0% |
| Anhui XDLK Microsystem 688582.SS | China | $1.95B | -36% | -38% | 21% | 37.3× | 55.7% | +37.0% |
| Heron Neutron Medical 7799.TW | Taiwan | $1.94B | +15% | n/a | -5,071% | 380.6× | n/a | n/a |
| Xi'an Taijin New Energy & Materials Sci-Tech 688813.SS | China | $1.93B | -13% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Guotai International 002091.SZ | China | $1.91B | -11% | +7% | 6% | 10.0× | -20.9% | +5.5% |
| Insperity NSP | United States | $1.90B | +53% | +2% | 0% | 19.9× | 19.5% | +9.7% |
| Hui Lyu Ecological Technology Groups 001267.SZ | China | $2.61B | -59% | +90% | 10% | 71.6× | n/a | n/a |
| International Workplace IWG.L | United Kingdom | $2.63B | +12% | 0% | 4% | 22.5× | 33.6% | +3.3% |